Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Drug toxicity: Drug–Drug Interaction

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...

Tonsillitis II: Management

Tonsillitis II: Management

This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Factors influencing diabetes treatment satisfaction in the INtegrating DEPrEssioN and Diabetes treatmENT randomized clinical trial: A multilevel model analysis.

Diabetic medicine : a journal of the British Diabetic Association·2024

Same author

Effect of nitrogen (N) deposition on soil-N processes: a holistic approach.

Scientific reports·2020

Same author

Responses of diversity, productivity, and stability to the nitrogen input in a tropical grassland.

Ecological applications : a publication of the Ecological Society of America·2019

Same author

The INtegrating DEPrEssioN and Diabetes treatmENT (INDEPENDENT) study: Design and methods to address mental healthcare gaps in India.

Contemporary clinical trials·2017

Same author

Training sensory signal-to-noise resolution in children with ADHD in a global mental health setting.

Translational psychiatry·2016

Same author

Biomarkers to enhance accuracy and precision of prediction of short-term and long-term outcome after spontaneous intracerebral haemorrhage: a study protocol for a prospective cohort study.

BMC neurology·2015

Search research articles

Related Experiment Videos

Bleeding gums: duloxetine may be the cause.

Yps Balhara¹, R Sagar, S T Varghese

¹Department of Psychiatry and National Drug Dependence Treatment Centre, AIIMS, New Delhi, India. ypsbalhara@rediffmail.com

Journal of Postgraduate Medicine

|January 25, 2007

Summary

Duloxetine, used for diabetic pain and depression, commonly causes nausea and fatigue. A rare side effect of bleeding gums was observed in one patient, resolving after drug discontinuation.

Related Experiment Videos

Area of Science:

Pharmacology
Clinical Medicine
Adverse Drug Events

Background:

Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) indicated for major depressive disorder and neuropathic pain.
Commonly reported side effects include nausea, dry mouth, somnolence, and gastrointestinal disturbances.
Understanding the full spectrum of adverse events is crucial for patient safety.

Observation:

A case report details a patient experiencing bleeding gums shortly after initiating duloxetine therapy.
The oral bleeding symptom resolved upon cessation of the medication.
This observation suggests a potential, albeit rare, association between duloxetine and gingival bleeding.

Findings:

Gingival bleeding is not a commonly listed adverse event associated with duloxetine.
The temporal relationship between drug initiation and symptom onset, followed by resolution upon discontinuation, supports a potential causal link.
This case highlights the importance of considering less frequent adverse drug reactions.

Implications:

Clinicians should be aware of the possibility of rare adverse events like gingival bleeding with duloxetine.
Further investigation may be warranted to determine the mechanism and prevalence of this side effect.
This case contributes to the pharmacovigilance data for duloxetine, aiding in comprehensive risk assessment.